

Suprachoroidal CLS-TA Improves Visual Acuity and Macular Edema in Noninfectious Uveitis: Results of the Phase 3 PEACHTREE Study

Steven Yeh, MD M. Louise Simpson Associate Professor of Ophthalmology Faculty Fellow, Emory Global Health Institute Emory Eye Center

> 42nd Annual Macula Society Meeting Bonita Springs, FL February 13-16, 2019



Financial Disclosures

- Clearside Biomedical, Inc. (Consultant)
- Santen (Consultant)
- AGTC (Consultant)
- Research to Prevent Blindness (Grant)
- Marcus Foundation Combating Childhood Illness Seed Funding (Grant)




Thank You to the PEACHTREE Investigators!





Macular Edema Due to Noninfectious Uveitis


- Macular edema (ME) is the leading cause of vision impairment and vision loss in uveitis¹
- Commonly observed across anatomic subtypes of uveitis
 - 34-66% of intermediate, posterior, panuveitis
 - 11% of anterior uveitis
- Macular edema may persist despite adequate control of inflammation



- 2. Lardenoye CWTA et al, *Ophthalmology*. 2006;113:1446-1449;
- 3. Tomkins-Netzer et al, *Ophthalmology*. 2015;122:2351-2359.


^{1.} Dick AD, Br J Ophthalmol. 1994;78:1-2;





- Favorable drug concentrations: Retina, RPE, choroid >> Anterior segment
- Potential for uveitic macular edema with fewer side effects

PEACHTREE: Phase 3 Randomized, Controlled Double-Masked, Multicenter Trial



- Primary endpoint: Proportion of subjects gaining ≥15 ETDRS letters in BCVA at week 24
- 3:2 randomization of suprachoroidal CLS-TA vs. sham procedure

Key Inclusion and Exclusion Criteria

Inclusion

EMORY

- Macular edema with central subfield thickness ≥300 microns
- Noninfectious uveitis of any associated diagnosis/etiology
- Any anatomic location: anterior, intermediate, posterior and panuveitis
- Disease activity: Active or controlled inflammation
- Visual acuity: 20/800 to 20/40 (≥ 5 to ≤ 70 ETDRS letters)

Exclusion

- Any ocular disease or active infection in the study eye other than uveitis
- Intraocular pressure >22 mmHg or uncontrolled glaucoma
- Subjects ≤22 mmHg could be on up to 2 IOP-lowering medications




Baseline Subjects Characteristics -Similar Between Treatment Groups

Characteristics	CLS-TA N=96	Control N=64	Overall N=160
Gender, n (%)	N-50	N-04	N-100
Male	42 (43.8)	30 (46.9)	72 (45.0)
Female	54 (56.3)	34 (53.1)	88 (55.0)
Age (years), mean (SD)	50.40 (14.2)	50.0 (15.1)	50.2 (14.5)
BCVA, study eye (ETDRS letters)			
Mean (SD)	54.7 (13.9)	53.5 (12.9)	54.2 (13.5)
Median (range)	57 (9 – 89)	54 (12-79)	56 (9-89)
CST, study eye (μm)			
Mean (SD)	480.9 (153.2)	525.4 (158.1)	498.7 (156.3)
Median (range)	453.0 (256-857)	518.5 (274-971)	481.5 (256-971)


All Anatomic Subtypes Enrolled

EMORY





PEACHTREE Met Its Primary Efficacy Endpoint




Intention-to-treat population; LOCF imputation.

The *p*-value is based on a CMH Cochran-Mantel-Haenszel test for general association between treatment and response with stratification by country. ETDRS, Early treatment diabetic retinopathy study; LOCF, last observation carried forward.

Mean Change in BCVA

Improvement From as Early as Week 4 Through Week 24 in the CLS-TA Arm



Intention-to-treat population; LOCF imputation.

t-test. Differences between the CLS-TA and control arms were significant at each visit.


BCVA, best corrected visual acuity.

EMORY

BCVA Mean Change from Baseline by Anatomic Location

EMORY


Ś



12

Mean Change in Central Subfield Thickness


Improvement From as Early as Week 4 through Week 24 in CLS-TA Arm



Intention-to-treat population; LOCF imputation. CST, central subfield retinal thickness.


EMORY

Mean Change from Baseline in CST by Anatomic Location



EMORY


NO.



14

EMORY


Anterior Chamber and Vitreous Inflammation: % Subjects with Resolution, Week 24



P<0.001 for all comparisons (AC Cell, AC Flare, Vitreous Haze)



Kaplan-Meier Analysis: Time to Rescue






MAGNOLIA: Prospective, Non-interventional, Masked, Observational 24-week Extension Trial




- To be eligible for MAGNOLIA, subjects must have completed PEACHTREE and **NOT** have received rescue medication
- Primary Endpoint: Time to rescue therapy relative to Day 0 of PEACHTREE



Kaplan-Meier: Time to First Rescue – Primary Endpoint

EMORY





Serious AEs

- No deaths
- Three SAEs in CLS-TA arm: none considered treatment-related
 - Two non-ocular (sialoadenitis, lumbar vertebral fracture)
 - One ocular (retinal detachment approximately 8 weeks after injection)


Ocular AEs, Study Eye	CLS-TA 4.0 mg N=96 n (%)	Control N=64 n (%)
Number of subjects with ≥1 ocular AEs	49 (51.0)	37 (57.8)
Treatment-related ocular AEs	29 (30.2)	8 (12.5)

Ocular AEs

• AEs occurring in >5% subjects in the CLS-TA arm included: elevated IOP, eye pain, cataract



Elevated IOP Adverse Events




"Elevated IOP" includes (a) increased IOP, (b) ocular hypertension, and (c) glaucoma.

AE, adverse event; IOP, intraocular pressure.



Cataract Adverse Events



- New or worsening cataracts occurred with similar frequency in the CLS-TA and control groups
- No cataract-related surgeries in this trial

"Cataract" includes (a) cataract, (b) cataract subcapsular, and (c) cataract nuclear.



PEACHTREE Study: Take Home Points

Efficacy

- Primary endpoint was met, with ~47% of patients gaining ≥15 ETDRS letters
- Suprachoroidally injected CLS-TA significantly improved vision and macular edema in uveitis at all anatomical locations
- Anterior segment and vitreous inflammation resolved in the majority of CLS-TA patients

Safety

- Low rates of elevated IOP and cataract
- No SAEs attributed to CLS-TA



THANK YOU